This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yarosh, W. Articles by Huang, T. Search for Related Content PubMed PubMed Citation Articles by Yarosh, W. Articles by Huang, T.

TBX3 Is Overexpressed in Breast Cancer and Represses p14^ARF by Interacting with Histone Deacetylases

¹ Department of Pediatrics, Division of Human Genetics, ² Department of Pathology and Laboratory Medicine, ³ Department of Medicine, Epidemiology Division, and ⁴ Department of Developmental and Cell Biology, University of California, Irvine, California

Requests for reprints: Taosheng Huang, Division of Genetics, Department of Pediatrics, Developmental & Cell Biology and Pathology, 314 Robert R. Sprague Hall, University of California, Irvine, CA 92697. Phone: 949-824-9346; Fax: 949-824-9776; E-mail: huangts{at}uci.edu.

Key Words: TBX3 • HDACs • p14^ARF • breast cancer • immunohistochemistry • immunoprecipitation • immunofluorescence • HDACI

TBX3 is a transcription factor of the T-box gene family. Mutations in the TBX3 gene can cause hypoplastic or absent mammary glands. Previous studies have shown that TBX3 might be associated with breast cancer. Here, we show that TBX3 is overexpressed in malignant cells of primary breast cancer tissues by immunohistochemistry. TBX3 interacts with histone deacetylases (HDAC) 1, 2, 3, and 5. TBX3 interacts with HDAC1, 2, and 3 via two distinct binding sites. However, deletion of the repression domain (amino acids 566–624) of TBX3 completely abolishes its interaction with HDAC5. Endogenous TBX3 and HDACs interaction and colocalization are found in a breast cancer cell line by coimmunoprecipitation and immunofluorescence, respectively. The functional significance of the interaction between TBX3 and HDAC is also tested in a p14^ARF-luciferase reporter system. Results indicate that TBX3 represses expression of p14^ARF tumor suppressor and that a HDAC inhibitor is able to reverse the TBX3 repressive function in a dosage-dependant manner. This study suggests that TBX3 may function by recruiting HDACs to the T-box binding site in the promoter region. TBX3 repression to its targets is dependent on HDAC activity. TBX3 may serve as a biomarker for breast cancer and have significant applications in both breast cancer diagnosis and treatment. [Cancer Res 2008;68(3):693–9]

This article has been cited by other articles:

				B. Jin, B. Yao, J.-L. Li, C. R. Fields, A. L. Delmas, C. Liu, and K. D. Robertson DNMT1 and DNMT3B Modulate Distinct Polycomb-Mediated Histone Modifications in Colon Cancer Cancer Res., September 15, 2009; 69(18): 7412 - 7421. [Abstract] [Full Text] [PDF]

				M. Rodriguez, E. Aladowicz, L. Lanfrancone, and C. R. Goding Tbx3 Represses E-Cadherin Expression and Enhances Melanoma Invasiveness Cancer Res., October 1, 2008; 68(19): 7872 - 7881. [Abstract] [Full Text] [PDF]